Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Core Insights - Zentalis Pharmaceuticals has initiated the DENALI Part 2a clinical trial for azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC), with topline data expected by the end of 2026, potentially supporting accelerated approval from the FDA [1][6][9] - The company reported a cash position of $332.5 million as of March 31, 2025, which is projected to fund operations into late 2027 [5][7][19] Company Developments - The first patient has been dosed in Part 2a of the DENALI clinical trial, which aims to confirm the primary dose of azenosertib with a target enrollment of approximately 30 patients at two dose levels [6][9] - Azenosertib has shown clinically meaningful response rates in previous studies, with an objective response rate (ORR) of 34.9% and a median duration of response (mDOR) of 6.3 months in patients with Cyclin E1+ PROC [6][12] Financial Performance - Research and development expenses for Q1 2025 were $27.2 million, a decrease from $49.6 million in Q1 2024, primarily due to reductions in clinical expenses and other operational costs [12][16] - General and administrative expenses also decreased to $10.6 million in Q1 2025 from $15.7 million in Q1 2024, mainly due to lower non-cash stock-based compensation [12][16] Upcoming Events - Zentalis plans to participate in several upcoming scientific and investor conferences, including the ASCO Annual Meeting and the Jefferies Healthcare Conference [4][6]